Regeneron On Genetics R&D: 'It's Our Oxygen'
Executive Summary
Regeneron is pointing to early research in genetics as the lifeline that will deliver new drugs into the clinic as Eylea matures, new blockbusters have yet to materialize and investors grow restless.
You may also be interested in...
Genomics Data Should Get More Attention In FDA Drug Review And Labeling, Regeneron Says
Regeneron advocates industry-FDA collaboration to establish regulatory standards for novel applications of genomic data, such as determining whether long-term outcomes studies are needed, and inclusion of the data in product labeling.
Novel Regeneron Deal Puts Partner Decibel In The Driver's Seat
Regeneron signed a unique agreement with the hearing-focused start-up Decibel in which it will make a minority equity investment and pay R&D costs, but leave full commercialization rights with its partner. The deal sprang from Regeneron’s outreach to venture-backed biotechs.
Keeping An Eye On Regeneron: What's Next To Drive Growth
Regeneron is looking to expansion of Eylea to diabetic retinopathy and Dupixent to asthma and other indications to drive mid-term growth. The firm is poised to file a PD-1 inhibitor with FDA in Q1.